Corporate Communications:
Dr. Lise Hébert
(450) 680-4500
Toll free (877) 680-4500

If you need additional assistance or information regarding the company, please send an Email to: webinfo@neurochem.com.

December 19, 2003

- Neurochem added to S&P/TSX Composite Index.

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - today announced that it has been selected to be added to the S&P/TSX Composite Index scheduled to take effect after the close of business...

December 11, 2003

- Francesco Bellini:
2003 Personnality of the year in Business Category

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - Dr. Francesco Bellini, chairman and CEO of Neurochem, has been named Personality of the Year for 2003, in the Business category, by...

December 9, 2003

- Annual General & Special Meeting of Shareholders.
Neurochem announces continued positive results for Alzhemed™ in open-label phase 2 extension study for the treatment of Alzheimer's disease.

At its annual general and special meeting of shareholders, Neurochem Inc. (NASDAQ: NRMX, TSX: NRM) announced today additional positive interim results on cognitive function as...

December 8, 2003

- Neurochem's Annual General and Special Shareholders' meeting and media briefing session.

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - Dr. Francesco Bellini, Chairman and Chief Executive Officer of Neurochem Inc., invites the news media to the Annual General and Special...

November 13, 2003

- Neurochem Added to NASDAQ Biotech Index.

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - today announced that it has been selected to be added to the NASDAQ Biotechnology Index (NBI) effective on Monday, November 24...

November 12, 2003

- Neurochem Announces First Quarter Results for Fiscal 2004.
Successfully completes U.S. Initial Public Offering and raises $85.0 million, lists on Nasdaq, advances clinical trials, changes fiscal year-end.

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - today announced its results for the first quarter of fiscal 2004, ended September 30, 2003. Milestones for the period included the successful...

November 10, 2003

- Neurochem to release Q1 2004 Results.

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - today announced that on Wednesday, November 12, 2003, it will release its first quarter 2004 results for the period ended September 30, 2003...

November 6, 2003

- Neurochem to present at CIBC World Markets Fourteenth Annual Healthcare Conference.

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today that it will present at the CIBC World Markets 14th Annual Healthcare Conference taking place from November 10th to 12th...

November 4, 2003

- Interim results of Alzhemed™ open-label phase 2 extension study demonstrates cognitive benefits in patients with Alzheimer's disease.

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today positive results on cognitive function as measured by ADAS-cog1 of patients suffering from mild-to-moderate Alzheimer's Disease...

September 25, 2003

- Neurochem Inc. announces underwriter's exercise of over-allotment option.

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today that it will issue on or about September 26, 2003 an additional 750,000 common shares at US$10.87 per share to the...

September 18, 2003

- Neurochem Inc. prices Public Offering of 5 million common shares for gross proceeds of US $ 54 million.

Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today that its registration statement has become effective under the U.S. Securities Act of 1933 and that it has obtained a receipt for a final...

August 20, 2003

- Neurochem Inc. files preliminary prospectus with Canadian and U.S. Securities Authorities for Common Share Offering.

Neurochem, Inc. (TSX: NRM) - announced today that it has filed a short form preliminary prospectus with the Canadian securities regulators and a registration statement with the U.S. Securities...

August 18, 2003

- Neurochem Reports on Fourth Quarter and 2003 Year End Results.
Strategic focus on diseases of Central Nervous System and promising results on Phase II trial for Alzheimer candidate drug.

Neurochem, Inc. (TSX: NRM) - In announcing its results for the fourth quarter and 2003 fiscal year ended June 30, 2003, Neurochem Inc. (TSX: NRM) highlighted two milestones in its...

June 23, 2003

- Neurochem Conference Call and WebCast on Alzhemed™ Phase II Study for Alzheimer's Disease at 10:00AM today.

Neurochem, Inc. (TSX: NRM) - will host a teleconference and web cast at 10:00 A.M., ET, today, June 23, 2003, to discuss the findings of its Phase II study on Alzhemed™, it investigational...

June 23, 2003

- Neurochem reports promising findings from Alzhemed™ Phase II Study for Alzheimer's Disease.

Neurochem, Inc. (TSX: NRM) - announced today a preliminary analysis of the data from its recently completed Phase II clinical trial for the investigational drug candidate, Alzhemed™, in...

June 11, 2003

- Renal amyloidosis worsens the Familial Mediterranean
Fever prognosis.
Study highlights need for specific therapy for AA amyloidosis.

Neurochem, Inc. (TSX: NRM) - World Congress of Nephrology, Berlin, Germany - Data presented today show that the occurrence of renal amyloidosis (RA) worsens the Familial Mediterranean...

May 30, 2003

- Neurochem to present at the Annual UBS Warburg Global Specialty Pharmaceuticals Conference.

Neurochem, Inc. (TSX: NRM) - announced today that Francesco Bellini, Ph.D., Chairman and CEO of Neurochem, will present at the annual UBS Warburg Global Specialty Pharmaceuticals...

May 14, 2003

- Neurochem Reports on Third Quarter.
Finalizes additional financing, further strengthens senior management, reinforces focus on diseases of the central nervous system.

Neurochem, Inc. (TSX: NRM) - In announcing its results for the third quarter ended March 31, 2003, Neurochem Inc. (TSX: NRM) reported the finalization of additional financing during the...

May 13, 2003

- Neurochem to release Q3 2003 Financial Results.

Neurochem, Inc. (TSX: NRM) - Neurochem announced today that it will release its third quarter 2003 financial results on Wednesday, May 14, 2003...

May 7, 2003

- Neurochem licenses its Diabetes Technology to Innodia Inc
Neurochem to Focus on Diseases of the Central Nervous System

Neurochem, Inc. (TSX: NRM) - and Innodia Inc. announced today the conclusion of an agreement whereby Neurochem has licensed to Innodia Inc. its intellectual property rights relating to...

April 11, 2003

- Appointment to the Board of Directors

Neurochem, Inc. (TSX: NRM) - today announced the appointment of Mr. Richard Cherney as a director of the Company. Mr. Cherney is currently a partner specializing in corporate and securities law...

April 10, 2003

- Neurochem's Data Safety Monitoring Board recommends continuation of pivotal phase II/III clinical trial for Fibrillex™.
Second Unanimous Recommendation from Data Safety Monitoring Board.

Neurochem, Inc. (TSX: NRM) - A specialty pharmaceutical company focused on disorders of the central nervous system and amyloid-related diseases, announced today that, following the...

February 18, 2003

- Neurochem receives disinterested shareholder approval for second investment by Picchio Pharma Inc.

Neurochem, Inc. (TSX: NRM) - Announced today that the requisite majority of its disinterested shareholders approved the previously announced transaction by a subsidiary of Picchio Pharma Inc...

February 13, 2003

- Neurochem Reports on Second Quarter.
Major additions to senior management and board.
Additional financing.
Completed patient recruitment for Fibrillex™ pivotal phase II/III trial.

Neurochem, Inc. (TSX: NRM) - In announcing its results for the second quarter ended December 30, 2002, Neurochem Inc. (TSX: NRM) reported revenues of $229,000 and a net loss of...

February 12, 2003

- Neurochem to release Q2 2003 financial results.

Neurochem, Inc. (TSX: NRM) - Neurochem announced today that it will release its second quarter 2003 financial results Thursday, February 13, 2003, at 4:30 P.M. Eastern Time...

January 30, 2003

- Neurochem lead investigator awarded NIH grant to support U.S. phase II clinical trials of Cerebril™.
Trials to evaluate use of Cerebril for prevention of recurrent Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy.

Neurochem, Inc. (TSX: NRM) - Steven M. Greenberg, M.D., Ph.D., Associate Professor of Neurology at Harvard Medical School and Co-Director of the Neurology Clinical Trials Unit at...

January 27, 2003

- Neurochem to present at the annual U.S. Bancorp Piper Jaffray Healthcare Conference.

Neurochem, Inc. (TSX: NRM) announced today that it will present at the annual U.S. Bancorp Piper Jaffray Healthcare Conference taking place from January 28-30, 2003, at the Pierre Hotel in...

January 7, 2003

- Neurochem to present at the 21st Annual JP Morgan H&Q Healthcare Conference.

Neurochem, Inc. (TSX: NRM) announced today that it will present at the 21st Annual JP Morgan H&Q Healthcare Conference taking place from January 6-9, 2003 at the Westin St. Francis Hotel in...

January 6, 2003

- Neurochem appoints Dr. Philippe Calais as new President.

Dr. Francesco Bellini, Chairman and CEO of Neurochem Inc. (TSX:NRM), is pleased to announce the appointment of Dr. Philippe Calais as President of Neurochem, effective January 6, 2003...

Our site is best viewed with IE4+ at a resolution of 1024×768.
All contents copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.